Bristol Myers Squibb
-
Bristol Myers Squibb pledges US$40B to boost US operations
This initiative aims to strengthen domestic pharmaceutical production, improve supply chain control, and accelerate innovation through advanced technologies like artificial intelligence and machine learning.
-
-
-
-
-
Bristol Myers Squibb adjusts sales projections as challenges loom
USA — Bristol Myers Squibb, a prominent pharmaceutical company, has recalibrated its sales expectations for its newer medicines, signaling a more gradual revenue growth trajectory…
-
Bristol Myers Squibb to acquire Mirati Therapeutics, bolstering oncology portfolio
USA — Bristol Myers Squibb has entered into an agreement to acquire Mirati Therapeutics for US$4.8 billion, in a move aimed at solidifying its position…
-
BMS and Evotec forge enhanced neurology alliance, now valued at US$4 Billion
USA — Pharmaceutical company Bristol-Myers Squibb (BMS) has once again expanded its collaboration with Evotec, a drug discovery and development company. BMS has paid another…
-
Pricing hurdles force Bristol Myers to abandon plans for launching new cancer drug in Germany
GERMANY — Bristol Myers Squibb, following its European approval last September, has announced that it will not be launching Opdualag, an infusion of Opdivo and…
-
Bristol Myers buys Turning Point Therapeutics for US$4B, strikes up Roche rivalry
UNITED KINGDOM – Bristol Myers Squibb has acquired Turning Point Therapeutics in a US$4.1 billion deal and a new cancer asset slated to hit the…